Study Of Use Of Antituberculosis Drugs (OAT) In One Of The Hospitals In Jember District
DOI:
https://doi.org/10.36858/jmid.v3i2.38Keywords:
Pulmonary TB; Antituberculosis Drugs; OAT; Drug useAbstract
Abstract
Background: Tuberculosis (TB) is a long-term infectious disease caused by the bacterium Mycobacterium tuberculosis. Successful management of pulmonary TB will reduce the rate of disease transmission and the risk of death. TB treatment is carried out routinely over a period of time under the supervision of a Drug Companion (PMO).]
Purpose: This study aims to identify the type of TB treatment received by patients and the duration of treatment.
Methods: This is a descriptive study. Data collection on study subjects was conducted retrospectively using medical records of TB patients undergoing anti-TB treatment (OAT) therapy from January to December 2023. Sampling used a purposive sampling technique, with a sample size of 73.
Results: The study showed that the majority of patients were male (60.3%), and the majority were aged 17-25 years (32.9%). Most patients used FDC drugs with a treatment duration of 0-6 months.
Conclusions: Most study subjects received anti-TB therapy with a treatment duration of 0-6 months.
References
Kemenkes RI. 2020. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberkulosis. Jakarta: Kementerian Kesehatan Republik Indonesia.
Nguyen Hv, Tiemersma E, Nguyen Nv, Nguyen Hb, Cobelens F. 2023. Disease Transmission by Patients with Subclinical Tuberculosis. Clinical Infectious Diseases. 76(11):2000–6.
Umar F. 2023. Mycobacterium Tuberculosis: Kajian Mekanisme Resistensi Intrinsik dan Resistensi Genetik terhadap Obat Antituberkulosis. Majalengka, Jawa Barat: PT. Pusat Literasi Dunia.
Dachi S, Alyakin Dachi R, Ester Sitorus Mj, Nababan D, Lina Tarigan F. 2024. Faktor yang Berhubungan dengan Kepatuhan Minum Obat Antituberkulosis (OAT) Pada Pasien TB Paru di Wilayah Kerja Puskesmas Lahomi Kecamatan Lahomi Kabupatan Nias Barat. 8(1).
WHO. 2023. Global Tuberculosis Report 2023. Geneva: World Health Organization.
Kemenkes RI. 2023. Indonesia Raih Rekor Capaian Deteksi TB Tertinggi di tahun 2022. Jakarta: Kementerian Kesehatan Republik Indonesia.
Dinkes Jatim. 2023. Profil Kesehatan Provinsi Jawa Timur Tahun 2022. Surabaya: Dinas Kesehatan Kota Surabaya.
Handayani I, Syahputra Siregar I, Noviani W. 2023. Faktor-Faktor Penyebab Terjadinya Tuberkulosis Paru di Puskesmas Binjai Estate tahun 2022. Jurnal Maternitas Kebidanan. 8(1).
Anuku T, Pareta D, Kanter J, Untu S. 2020. Evaluasi Rasionalitas Penggunaan Obat Antituberkulosis Pada Pasien Tuberkulosis Paru di Puskesmas Ibu Kabupaten Halmahera Barat. Jurnal Biofarmasetikal Tropis 2020. 3(1):101–7.
Nurul Hikmah et al. 2023. Gambaran Penggunaan Obat Antituberkulosis (OAT) Pada Pasien Rawat Jalan di Puskesmas Cipayung Kota Depok Tahun 2022. Jurnal Farmasi Kryonaut. 2:8–13.
Rahmad Dd, Purnama A. 2024. Limfadenopati Tuberkulosis dengan Drugs-Induced Hepatitis (DIH) di Sikka, Nusa Tenggara Timur, Indonesia. Cermin Dunia Kedokteran. 51(1):32–6.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Fitri Amirah Nahdah Salsabilah, Wima Anggitasari
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
